Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Abstract

Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38).

Biologics for psoriasis: What is new?

“…TH17 cells secrete IL‐17A, which has been shown to promote psoriatic skin changes. Consequently, after clarification of these main pathological mechanisms, TNF‐α, IL‐23, and IL‐17A have been accepted as key targets for psoriasis therapy (Lee, Amin, Bhutani, & Wu, ; Tsai & Tsai, ).…”

“…Case reports reported efficacy of Gevokizumab (target: IL1), Canakinumab (target: IL1), Anakinra (target: IL1R), Basiliximab (target: IL2R), and Tocilizumab (target: IL6R) in patients with GPP and/or PPPP (Tsai & Tsai, ; Table ).…”

“…IL2R), and Tocilizumab (target: IL6R) in patients with GPP and/or PPPP (Tsai & Tsai, 2017; Table 1).…”

Integration of immunome with disease-gene network reveals common cellular mechanisms between IMIDs and drug repurposing strategies

“…In addition to the drug targets revealed from the DIME-drug network of Crohn’s disease, the pleiotropy drug network of Crohn’s disease and psoriasis ( Figure 4C ), comprised some known drug targets such as IL6R for psoriasis and IL1B for Crohn’s disease. The associated drug of IL6R, tocilizumab is known to be used in the treatment for psoriasis 64 . Interestingly, anti IL6 therapy has been shown to have promising clinical response for Crohn’s disease as well 65 .…”

Targeting granulocyte‐monocyte colony‐stimulating factor in psoriasis. What a negative study can teach us

“…RA responds to antibodies to IL‐1 and IL‐6 whereas psoriasis responds to antibodies targeting IL‐17 and IL‐23. Additionally, clinical trials of antibodies to IL‐8, which works in synergy with GM‐CSF to induce neutrophil chemotaxis, also failed to show efficacy in psoriasis …”